{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"50.188","value":"31.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"}],"units":"Participants"}],"title":"24 weeks after first course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.769","value":"34.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"384"}],"units":"Participants"}],"title":"24 weeks after second course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.912","value":"36.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"}],"units":"Participants"}],"title":"24 weeks after third course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.393","value":"39.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"}],"units":"Participants"}],"title":"24 weeks after fourth course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.309","value":"33.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"title":"24 weeks after fifth course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.197","value":"29.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"title":"24 weeks after sixth course"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.336","value":"24.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"title":"24 weeks after seventh course"}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"}],"units":"Participants"}],"description":"The ACRn is calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (patient's assessment of disease activity; patient's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value \\[either CRP or ESR\\]). The index of improvement in RA, where 0 indicates no improvement and 100 indicates a 100% improvement across all signs and symptoms of RA. ACRn scores were calculated considering the original baseline in the precursor studies WA16291 or WA17043.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received rituximab 1 gram IV on Days 1 and 15 of each course of retreatment. In addition, participants received methotrexate 10-25 mg/week orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid \\>=5 mg/week or equivalent. Participants received retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first \\[Day 1\\] infusion of the last course of rituximab). Repeat treatment was based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints \\>=2.6). Retreatment with rituximab was continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever occurred earlier.","id":"OG000","title":"Rituximab"}],"paramType":"MEAN","populationDescription":"ITT Population. Here, number of participants analyzed = participants who were evaluable for this outcome. Number analyzed = participants who were evaluable for specified category.","reportingStatus":"POSTED","timeFrame":"24 weeks after first, second, third, fourth, fifth, sixth, and seventh course of rituximab (median duration of 26, 90.9, 162.9, 232, 297.3, 354.4, and 406.7 weeks, respectively)","title":"American College of Rheumatology Index of Improvement (ACRn) Response","type":"SECONDARY","unitOfMeasure":"units on a scale"}